ClinicalTrials.gg
Not yet recruitingNCT07247786MIGRANTUpdated May 5, 2026

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

A Phase 2 interventional study of Biological: Fecal Microbiota Transplantation and Durvalumab in Non Small Cell Lung Cancer and Respiratory Tract Neoplasm, sponsored by Fundación GECP. Not yet recruiting at 20 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Fundación GECP · Phase 2, Interventional, and Treatment

How we know · 9 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP — 8 open to participants now, 13 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Fundación GECP.

Planned enrollment
6th of 13
68 · median 63
Started
2026
with 1 other
Phase 2
11 of 18
5 open now
Primary completion
2031-12
later than 10 of 12 live
Registered
18th of 18
by date

Among the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 10 of the 12 other live ones, and was the 18th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP, or all of them as a file.
02

Study summary

This is a randomized, phase II, multi-centre clinical trial.

Sample size: 68 patients (Experimental Arm (Durvalumab + chemotherapy + FMT capsules): 34 patients, Control Arm (Durvalumab + chemotherapy): 34 patients)

Population: Patients with stage IIA, IIB, IIIA and IIIB (only T3N2) non-small cell lung cancer

In the Experimental arm, patients will receive Fecal Microbiota Transplant. Once done, the patient will start neoadjuvant treatment with Durvalumab + Chemotherapy .

In the Control arm, patients will receive neoadjuvant treatment with Durvalumab + Chemotherapy.

After neoadjuvant/induction treatment every patient will be evaluated to decide if the patient is a candidate for surgery or not. Patients that are R0 after surgery will receive Adjuvant treatment with Durvalumab.

The primary objective is to evaluate the pathological Complete Response (pCR) rate.

The total trial duration will be 6.5 years approximately.

Read the detailed description

This is a randomized, phase II, multi-centre clinical trial stratified according to PDL1 status (≥50 % or \<50%), and Akkermansia positive vs negative.

In the pre-treatment phase, donors will be selected for preparing the fecal microbiota transplant with their samples.

After that, patient's candidate with stage IIA, IIB, IIIA and IIIB (only T3N2) non-small cell lung cancer to study will be randomized in two different arms.

In the Experimental arm, after randomization, patients will receive treatment with Rifaximin. Once done, the patient will start neoadjuvant treatment with Durvalumab IV + Chemotherapy for several cycles.

In the Control arm, after randomization patients will receive neoadjuvant treatment with Durvalumab IV + Chemotherapy for several cycles.

After neoadjuvant/induction treatment every patient will be evaluated by a multidisciplinary team in each participant hospital to decide if the patient is a candidate for surgery or not.

Patients that are R0 confirmed by surgical pathology evaluation after surgery will receive Adjuvant treatment with Durvalumab IV.

Sample size: 68 patients (Experimental Arm (Durvalumab + chemotherapy + FMT capsules): 34 patients, Control Arm (Durvalumab + chemotherapy): 34 patients)

The primary objective is to evaluate the pathological Complete Response (pCR) rate in the intention to treat population (ITT population)

The total trial duration will be 6.5 years approximately.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Respiratory Tract Neoplasm

Keywords

  • Non small cell lung cancer
  • Fecal microbiota transplant
  • Inmune checkpoint inhibitor responder
  • Neoadjuvant treatment
  • Adjuvant treatment
  • Durvalumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated patients with - or cytologically- documented NSCLC who present stage IIA, IIB, IIIA or IIIB (only T3N2) disease (according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology)
  • PET scan and brain CT or MRI at baseline to confirm the absence of distant disease
  • (Performance status) 0-1
  • Adequate hematologic and organ function.
  • All patients are notified of the nature of this study and signed a written in-formed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention
  • Adequate lung function: Forced Espiratoy Volumen in 1 second () >50% of normal volume and Difusion Capacity of the Lungs for Carbon Monoxide (DLCO) >40% of normal value
  • Patients aged ≥ 18 years at the time of study entry
  • Body weight > 30Kg (for durvalumab monotherapy)
  • PDL1 analyzed (value in %)
  • For female patients of , agreement (by patient and/or partner) to use a highly effective forms of that results in a low failure rate (\< 1% per year) when used consistently and correctly, and to continue its use for 6 months after the last dose of trial treatment.
  • For male patients with female partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception that results in a low failure rate when used consistently and correctly, and to continue its use for 6 months after the last dose of trial treatment.
  • Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drugs. The same rules are valid for male patients involved in this clinical study if they have a partner of childbirth potential. Male patients must always use a condom.
  • Women who are not (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 8 days prior to initiation of study drug.
  • Patients is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Presence of at least one by CT-SCAN, as defined by v1.1.
  • Patients with a ≥12 weeks.
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the US, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations

Exclusion criteria

Exclusion Criteria:

  • Patients with known sensitizing mutation or an amplification in the epidermal growth factor receptor (EGFR) gene or any variety of alterations of ALK oncogene.
  • Known STK-11 ligand alterations, MDM2 amplifications or ROS1 translocations.
  • Weight loss >10% within the previous 3 months.
  • Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
  • Patients with other active requiring concurrent intervention and/or concurrent treatment with other drugs or anti-cancer therapy
  • History of active primary immunodeficiency
  • History of another primary malignancy.
  • Active or prior documented or inflammatory disorders.
  • Patients with a condition requiring systemic treatment with either (>10 mg daily prednisone equivalent) or other medications within 14 days of randomization.
  • Pleural or pericardial effusion.
  • Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction.
  • Positive test for .
  • Patients with positive test for virus surface antigen (HBV sAg) or virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
  • Patients with history of allergy to study drug components/.
  • Active tuberculosis.
  • Severe infections within 4 weeks prior to be included in the study.
  • Major surgical procedure other than for diagnosis within 28 days prior to inclusion or anticipation of need for a major surgical procedure during the course of the study.
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.
  • Patients with medical, mental, neurological or psychological condition which in the opinion of the investigator would not permit the patient to understand the patient information sheet or comply with study procedures.
  • Treatment with any other investigational agent with therapeutic intent within 28 days prior to initiation of study treatment.
  • Patients with uncontrolled comorbidities that may affect the clinical trial compliance.
  • Women who are pregnant or in the breastfeeding period or male or female patients of who are not willing to employ effective from screening to 90 days after the last dose of durvalumab monotherapy.
  • Sexually active men and women of who are not willing to use an effective contraceptive method during the study.
  • Patients must be informed that they are not allowed to donate blood during the treatment period of this clinical trial.
  • Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.
  • Receipt of a within 30 days prior to the first dose of investigational product (IP).
  • Concurrent enrollment in another clinical study, except in cases where the study is observational (non-interventional) or the patient is in the follow-up phase of a previous interventional study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Experimental Arm (Durvalumab + chemotherapy + FMT capsules)

    The treatment begins with a dose of antibiotics and a fecal microbiota transplant (FMT). Neoadjuvant/Induction Treatment: Patients will receive intravenous (IV) Durvalumab in combination with IV Paclitaxel and Carboplatin, the latter administered at the end of the Paclitaxel infusion. Patients must discontinue study treatment if there is evidence of disease progression that precludes surgery. Patients with stable disease or partial response may still be considered for surgery. Surgery: After the induction treatment, each patient will be evaluated by a multidisciplinary team at their respective hospital to determine surgical eligibility. Adjuvant Treatment: Patients with R0 resection confirmed by surgical pathology after surgery will receive adjuvant treatment with IV Durvalumab for several cycles.

    Biological: Biological: Fecal Microbiota Transplantation · Drug: Durvalumab · Drug: Paclitaxel · Drug: Carboplatin (AUC 6)

  • Active comparator
    Control Arm (Durvalumab + chemotherapy)

    Neoadjuvant/Induction Treatment: Patients will receive intravenous (IV) Durvalumab in combination with IV Paclitaxel and Carboplatin, the latter administered at the end of the Paclitaxel infusion. Patients must discontinue study treatment if there is evidence of disease progression that precludes surgery. Patients with stable disease or partial response may still be considered for surgery. Surgery: After the induction treatment, each patient will be evaluated by a multidisciplinary team at their respective hospital to determine surgical eligibility. Adjuvant Treatment: Patients with R0 resection confirmed by surgical pathology after surgery will receive adjuvant treatment with IV Durvalumab for several cycles.

    Drug: Durvalumab · Drug: Paclitaxel · Drug: Carboplatin (AUC 6)

Interventions

  • BiologicalBiological: Fecal Microbiota Transplantation

    Patients who are going to be donors must have been treated with neoadjuvant chemoimmunotherapy as part of the NADIM studies and must have achieved a pathological complete response (pCR). Additionally, they must be free of disease and complications such as a second tumor or treatment-related toxicity. Samples must be collected from patients who achieved pCR after surgery. Patients in the Experimental Arm will receive an antibiotic treatment, followed by the administration of capsules as part of the fecal microbiota transplant (FMT).

  • Durvalumab is a human monoclonal antibody of the immunoglobulin G1 kappa (IgG1κ) subclass that inhibits binding of programmed cell death ligand (PD-L1). Durvalumab (MEDI4736) binds with high affinity and specificity to human PD-L1 and blocks its interaction with PD-1 and CD80. Pharmaceutical form: Concentrate for solution for infusion (sterile concentrate).Clear to opalescent, colorless to light yellow solution, with no visible particles. The solution has an approximate pH of 6.0 and an osmolality of approximately 400 mOsm/kg. Durvalumab will be administered as part of both the neoadjuvant and adjuvant phases of the study.

    Also known as: Imfinzi, MEDI4736

  • Neoadjuvant / induction treatment: Durvalumab Paclitaxel Carboplatin Neoadjuvant / induction treatment: 4 cycles will be administered prior to the assessment for surgery. Route of administration Paclitaxel: Intravenous infusion. Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion 200mg/m2 over 3 hours

  • DrugCarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant / induction treatment: Durvalumab Paclitaxel Carboplatin\* \*Infusion at the end of the Paclitaxel infusion. Neoadjuvant / induction treatment 4 cycles will be administered prior to the assessment for surgery. Route of administration Carboplatin: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center.

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) rate

    Pathological Complete Response (pCR) defined as the absence of residual tumor in lung and lymph nodes after surgery.

    Time frame: From date of randomization until the date of last follow up, assessed up to 24 months

Secondary outcomes

  1. Progression free survival (PFS)

    Progression free survival (PFS) defined as the time from initiation of treatment to the occurrence of disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: From date of randomization until the date of last follow up, assessed up to 24 months

  2. Overall Survival (OS)

    Overall survival (OS) defined as the time which begins at the start of treatment and up to the time of death or last follow up

    Time frame: From date of randomization until the date of last follow up, assessed up to 24 months

  3. Resectability rate (%)

    Resectability rate defined as the percentage of patients resected divided by the total number of patients who received neoadjuvant treatment

    Time frame: From date of randomization until the date of last follow up, assessed up to 24 months

  4. Proportion of R0 resections (%)

    Percentage of R0 resection will be calculated by dividing the total number of R0 resection patients by the total number of patients resected.

    Time frame: From date of randomization until the date of last follow up, assessed up to 24 months

  5. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Occurrence and severity of adverse events, with severity determined by NCI CTCAE v5.0 criteria.

    Time frame: From the subject's written consent to participate in the study through 90 days after the final administration of the drug.]

07

Study locations

20 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2031, 63 months later.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 63 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartEst.
Sep 15, 2026
Primary completionEst.
Dec 30, 2031
CompletionEst.
Dec 30, 2031
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247786
Lead sponsor
Fundación GECP
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Sep 15, 2026 (estimated)
Primary completion
Dec 30, 2031 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
May 5, 2026

Study contacts

Eva Pereira
Contact
gecp@gecp.org
+34934302006
Mariano Provencio, MD
study chair · President of Grupo Español de Cáncer de Pulmón

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion